GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Repare Therapeutics Inc (NAS:RPTX) » Definitions » Price-to-Operating-Cash-Flow

Repare Therapeutics (Repare Therapeutics) Price-to-Operating-Cash-Flow : (As of May. 14, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Repare Therapeutics Price-to-Operating-Cash-Flow?

As of today (2024-05-14), Repare Therapeutics's share price is $3.73. Repare Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.99. Hence, Repare Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Repare Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 7 years, Repare Therapeutics's highest Price-to-Operating-Cash-Flow Ratio was 201.44. The lowest was 4.26. And the median was 5.44.

RPTX's Price-to-Operating-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 26.57
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Repare Therapeutics's Cash Flow from Operations per share for the three months ended in Mar. 2024 was $0.27. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.99.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -115.00% per year.

During the past 7 years, Repare Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 7.20% per year. The lowest was -115.00% per year. And the median was -41.60% per year.


Repare Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Repare Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repare Therapeutics Price-to-Operating-Cash-Flow Chart

Repare Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial - - - 1,838.75 -

Repare Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Repare Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Repare Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Repare Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Repare Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Repare Therapeutics's Price-to-Operating-Cash-Flow falls into.



Repare Therapeutics Price-to-Operating-Cash-Flow Calculation

Repare Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=3.73/-1.994
=

Repare Therapeutics's Share Price of today is $3.73.
Repare Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.99.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Repare Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Repare Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Repare Therapeutics (Repare Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
7210 Frederick-Banting Street, Suite 100, Saint-Laurent, QC, CAN, H4S 2A1
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
Executives
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Michael Zinda officer: EVP, Chief Science Officer C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1
Susan Molineaux director C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
Davis Jerel director, 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures V, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage I, L.p. 10 percent owner ONE SANSOME, SUITE 1650, SAN FRANCISCO CA 94104
Thomas Civik director C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104

Repare Therapeutics (Repare Therapeutics) Headlines